Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type

Exclusion Criteria

• •Lymphoma histology other than MALT lymphoma or MALT lymphoma with a diffuse large cell lymphoma ("high grade lymphoma") - component
• •Use of any investigational agent within 28 days prior to initiation of treatment with lenalidomide
• •History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years
• •Major surgery, other than diagnostic surgery, within the last 4 weeks
• •Evidence of CNS involvement
• •A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
• •Severe peripheral polyneuropathy
• •Clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 6 months
• •Inadequate hematological status at baseline prior to study entry: Dependency on red blood cell and/or platelet transfusions, ANC (absolute neutrophil count (segmented + bands)) \< 1.0 x 109/L
• •Patients with active opportunistic infections
• •Pregnancy
• •Uncontrolled diabetes mellitus
• •Preexisting thromboembolic events at start of study